DGIdb - BLINATUMOMAB Drug Record

BLINATUMOMAB chembl:CHEMBL1742992 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MT-103

BLINATUMOMAB

MEDI-538

Drug Info:

FDA Approval not approved

Drug Class antibody

Drug Indications antineoplastic agent

(2 More Sources)

Publications:

Zugmaier et al., 2015, Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies., Mol. Immunol.

BLINATUMOMAB CD3D

Interaction Score: 3.79

Interaction Types & Directionality:

activator (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent

Trial Name MT-103

PMIDs:
25883042

Sources:
TdgClinicalTrial ChemblInteractions
BLINATUMOMAB CD247

Interaction Score: 2.94

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MT-103

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
BLINATUMOMAB CD19

Interaction Score: 2.72

Interaction Types & Directionality:

activator (activating)

antibody (inhibitory)

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD19 cross-linking agent

Direct Interaction yes

Trial Name MT-103

PMIDs:
25883042

Sources:
TdgClinicalTrial ChemblInteractions TTD
BLINATUMOMAB CD3E

Interaction Score: 1.77

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent

Direct Interaction yes

Trial Name MT-103

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions
BLINATUMOMAB BCR

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA
BLINATUMOMAB CD3G

Interaction Score: 1.36

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MT-103

Novel drug target Established target

Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions
BLINATUMOMAB ABL1

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA

TdgClinicalTrial: MT-103
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class antibody

FDA Approval not approved

Publications:
TTD: Blinatumomab
- Version: 2020.06.01
Alternate Names:

D0K4RK TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1742992
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1742992
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
PharmGKB: blinatumomab
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
FDA: Blinatumomab
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

FDA Approval	not approved
Drug Class	antibody
Drug Indications	antineoplastic agent

Direct Interaction	yes
Mechanism of Interaction	T cell surface glycoprotein CD3 cross-linking agent
Trial Name	MT-103

Mechanism of Interaction	B-lymphocyte antigen CD19 cross-linking agent
Direct Interaction	yes
Trial Name	MT-103

Trial Name	MT-103
Novel drug target	Established target
Mechanism of Interaction	T cell surface glycoprotein CD3 cross-linking agent

activator (activating)
antibody (inhibitory)

BLINATUMOMAB Drug Record

BLINATUMOMAB chembl:CHEMBL1742992 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

BLINATUMOMAB CD3D

Interaction Types & Directionality: activator (activating)

Interaction Info: Direct Interaction yes Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent Trial Name MT-103

PMIDs: 25883042

Sources: TdgClinicalTrial ChemblInteractions

BLINATUMOMAB CD247

Interaction Types & Directionality: n/a

Interaction Info: Trial Name MT-103 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

BLINATUMOMAB CD19

Interaction Types & Directionality: activator (activating) antibody (inhibitory)

Interaction Info: Mechanism of Interaction B-lymphocyte antigen CD19 cross-linking agent Direct Interaction yes Trial Name MT-103

PMIDs: 25883042

Sources: TdgClinicalTrial ChemblInteractions TTD

BLINATUMOMAB CD3E

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent Direct Interaction yes Trial Name MT-103

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions

BLINATUMOMAB BCR

Interaction Types & Directionality: n/a

Interaction Info: Fusion protein BCR:ABL1

PMIDs: None found

Sources: PharmGKB FDA

BLINATUMOMAB CD3G

Interaction Types & Directionality: n/a

Interaction Info: Trial Name MT-103 Novel drug target Established target Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions

BLINATUMOMAB ABL1

Interaction Types & Directionality: n/a

Interaction Info: Fusion protein BCR:ABL1

PMIDs: None found

Sources: PharmGKB FDA

TdgClinicalTrial: MT-103

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class antibody FDA Approval not approved

Publications:

TTD: Blinatumomab

Alternate Names: D0K4RK TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1742992

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1742992

Alternate Names:

Drug Info:

Publications:

PharmGKB: blinatumomab

Alternate Names:

Drug Info:

Publications:

FDA: Blinatumomab

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

activator (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent

Trial Name MT-103

PMIDs:
25883042

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MT-103

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

activator (activating)

antibody (inhibitory)

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD19 cross-linking agent

Direct Interaction yes

Trial Name MT-103

PMIDs:
25883042

Sources:
TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent

Direct Interaction yes

Trial Name MT-103

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MT-103

Novel drug target Established target

Mechanism of Interaction T cell surface glycoprotein CD3 cross-linking agent

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA

Drug Info:

Drug Indications antineoplastic agent

Drug Class antibody

FDA Approval not approved

Alternate Names:

D0K4RK TTD Drug ID